Lipid nanoparticles for delivering mRNA vaccines
Provided are novel lipid nanoparticles for delivering nucleic acids such as mRNA. Also provided are methods of making and using lipid nanoparticles for delivering nucleic acids such as mRNA.
1. A pharmaceutical composition comprising a nucleic acid molecule encapsulated in a lipid nanoparticle (LNP), wherein the LNP comprises:
a cationic lipid GL-HEPES-E3-E12-DS-4-E10 at a molar ratio between 35% and 45%,
a polyethylene glycol (PEG) conjugated (PEGylated) lipid at a molar ratio between 0.25% and 2.75% wherein the PEGylated lipid is DMG-PEG2000,
a cholesterol-based lipid at a molar ratio between 20% and 35% wherein the cholesterol-based lipid is cholesterol, and
a helper lipid at a molar ratio of between 25% and 35% wherein the helper lipid is 1,2-dioleoyl-SN-glycero-3-phosphoethanolamine (DOPE),
wherein all the molar ratios are relative to the total lipid content of the LNP.
2. The composition of claim 1 , wherein the LNP comprises:
GL-HEPES-E3-E12-DS-4-E10 at a molar ratio of 40%,
DMG-PEG2000 at a molar ratio of 1.5%,
cholesterol at a molar ratio of 28.5%, and
DOPE at a molar ratio of 30%.
3. The composition of claim 1 , wherein
the LNP has an average diameter of 30-200 nm or 80-150 nm.
4. The composition of claim 1 , wherein the nucleic acid molecule(s) is an mRNA molecule comprising an open reading frame (ORF).
5. The composition of claim 4 , wherein the mRNA molecule encodes an antigen.
6. The composition of claim 4 , wherein the antigen is derived from influenza virus.
7. The composition of claim 4 , wherein
the LNP comprises two or more mRNA molecules, wherein each mRNA molecule encodes a different antigen.
8. The composition of claim 7 , wherein the composition comprises two, three, four, five, six, seven, eight, nine, or more mRNA molecules encoding (i) one or more hemagglutinin (HA) antigens, (ii) one or more neuraminidase (NA) antigens, or (iii) at least one HA antigen and at least one NA antigen.
9. The composition of claim 6 , wherein the composition comprises one or more mRNA molecules encoding antigens of influenza A, B and/or C viruses.
10. The composition of claim 4 , wherein the mRNA molecule comprises an open reading frame (ORF) encoding a respiratory syncytial virus (RSV) F protein antigen.
11. The composition of claim 4 , wherein
the ORF is codon optimized.
12. The composition of claim 1 , wherein the composition is formulated for intramuscular injection.
13. The composition according to claim 8 , wherein the antigens comprise an influenza virus HA antigen and/or an influenza virus NA antigen having a molecular sequence identified or designed from a machine learning model.
14. The composition of claim 1 , wherein the composition comprises 1-10 mg/mL of the LNP.
15. The composition of claim 1 , wherein the LNP comprises 1-20 nucleic acid molecules.
16. The composition of claim 5 , wherein the antigen comprises a viral antigen or a bacterial antigen.
17. The composition of claim 7 , wherein the different antigens are from the same pathogen.
18. The composition of claim 7 , wherein the different antigens are from different pathogens.
19. The composition of claim 4 , wherein the composition comprises two or more LNPs, wherein each LNP comprises an mRNA encoding a different antigen.
20. The composition of claim 19 , wherein the different antigens are from the same pathogen.
21. The composition of claim 19 , wherein the different antigens are from different pathogens.
22. The composition of claim 9 , wherein the antigens are HA and/or NA antigens of influenza A and influenza B viruses.
23. The composition of claim 22 , wherein the HA antigens of influenza A viruses are selected from subtypes H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, H17, and H18; and/or the NA antigens of influenza A viruses are selected from subtypes N1, N2, N3, N4, N5, N6, N7, N8, N9, N10, and N11.
24. The composition of claim 22 , wherein the HA and NA antigens of Influenza B viruses are from the Influenza B/Yamagata lineage or the Influenza B/Victoria lineage.
25. The composition of claim 22 , wherein the composition comprises two, three, four, five, six, seven, eight, nine, or more mRNA molecules encoding (i) one or more HA antigens, (ii) one or more NA antigens, or (iii) a combination of one or more HA antigens and NA antigens selected from H1N1, H3N2, H2N2, H5N1, H7N9, H7N7, H1N2, H9N2, H7N2, H7N3, H5N2, and H10N7 subtypes and/or B/Yamagata and B/Victoria lineages.
26. The composition of claim 22 , wherein the composition comprises one mRNA molecule encoding an H3 HA antigen, one mRNA molecule encoding an H1 HA antigen, one mRNA molecule encoding an HA antigen from the Influenza B/Yamagata lineage, and one mRNA molecule encoding an HA antigen from the Influenza B/Victoria lineage.
27. The composition of claim 22 , wherein the composition comprises one mRNA molecule encoding an H3 HA antigen, one mRNA molecule encoding an N2 NA antigen, one mRNA molecule encoding an H1 HA antigen, one mRNA molecule encoding an N1 NA antigen, one mRNA molecule encoding an HA antigen from the Influenza B/Yamagata lineage, one mRNA molecule encoding an NA antigen from the Influenza B/Yamagata lineage, one mRNA molecule encoding an HA antigen from the Influenza B/Victoria lineage, and one mRNA molecule encoding an NA antigen from the Influenza B/Victoria lineage.
28. The composition of claim 10 , wherein the RSV F protein antigen comprises an amino acid sequence with at least 98% identity to SEQ ID NO: 16 or consists of an amino acid sequence of SEQ ID NO: 16.
29. The composition of claim 10 , wherein the RSV F protein antigen is in a pre-fusion conformation.
30. The composition of claim 10 , wherein the mRNA comprises a nucleic acid sequence with at least 80% identity to a nucleic acid sequence set forth in SEQ ID NO: 17.
31. The composition of claim 10 , wherein the mRNA comprises a nucleic acid sequence with at least 80% identity to a nucleic acid sequence set forth in SEQ ID NO: 21.
32. The composition of claim 10 , wherein the mRNA comprises of the following structural elements:
(i) a 5′ cap with the following structure:
(ii) a 5′ untranslated region (5′ UTR) having the nucleic acid sequence of SEQ ID NO: 19;
(iii) a protein coding region having the nucleic acid sequence of SEQ ID NO: 17;
(iv) a 3′ untranslated region (3′ UTR) having the nucleic acid sequence of SEQ ID NO: 20; and
(v) a poly(A) tail.
33. The composition of claim 4 , wherein-the mRNA molecule comprises at least one 5′ untranslated region (5′ UTR), at least one 3′ untranslated region (3′ UTR), and at least one polyadenylation (poly(A)) sequence.
34. The composition of claim 4 , wherein the mRNA comprises at least one chemical modification.
35. The composition of claim 4 , wherein at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% of the uracil nucleotides in the mRNA are chemically modified.
36. The composition of claim 4 , wherein at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% of the uracil nucleotides in the ORF are chemically modified.
37. The composition of claim 34 , wherein the chemical modification is selected from the group consisting of pseudouridine, N1-methylpseudouridine, 2-thiouridine, 4′-thiouridine, 5-methylcytosine, 2-thio-1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methyluridine, 5-methyluridine, 5-methoxyuridine, and 2′-O-methyl uridine.
38. The composition of claim 12 , wherein the composition comprises a phosphate-buffer saline; and/or the composition comprises trehalose.
39. The composition of claim 12 , wherein the composition comprises a phosphate-buffer saline; and/or the composition comprises trehalose at 10% (w/v) of the composition.
40. A kit comprising a container comprising a single-use or multi-use dosage of the composition of claim 1 .
41. The kit of claim 40 , wherein the container is a vial or a pre-filled syringe or injector.
42. A method of preparing the composition of claim 1 , comprising
providing an aqueous buffered solution comprising the nucleic acid molecule,
providing an amphiphilic solution comprising the cationic lipid, the PEGylated lipid, the cholesterol-based lipid, and the helper lipid, and
mixing the aqueous buffered solution and the amphiphilic solution at a ratio of 5:1 to 3:1, optionally 4:1.
43. The method of claim 42 , wherein the aqueous buffered solution is an acidic buffered solution.
44. The method of claim 43 , wherein the aqueous buffered solution comprises 1 mM citrate and 150 mM sodium chloride with a pH of about 4.5.
45. The method of claim 42 , wherein the amphiphilic solution is an ethanol solution.
46. A method of eliciting an immune response in a subject in need thereof, comprising administering to the subject an effective amount of the composition of claim 5 .
47. The method of claim 46 , wherein the composition is administered intramuscularly, intranasally, intravenously, subcutaneously, or intradermally.
48. The method of claim 46 , wherein the method comprises administering to the subject one or more doses of the composition, each dose comprising 1-250 μg of mRNA.
49. The method of claim 46 , wherein the method comprises administering to the subject one or more doses of the composition, each dose comprising 2.5, 5, 15, 45, or 135 μg of m RNA.
50. The method of claim 46 , wherein the method comprises administering to the subject two doses of the composition with an interval of 2-6 weeks.
51. A method of preventing influenza infections or reducing one or more symptoms of influenza infections, comprising administering to the subject an effective amount of the composition of claim 6 .
52. The method of claim 51 , wherein the composition is administered intramuscularly, intranasally, intravenously, subcutaneously, or intradermally.
53. The method of claim 51 , wherein the composition elicits an immune response against one or more seasonal and/or pandemic influenza strains.